Novo Nordisk’s phase III REDEFINE 1 study evaluating its next-gen subcutaneous obesity treatment ... SNY’s 21-valent Pneumococcal Jab Enters Phase III Sanofi and partner SK biosciences ...

Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...

Meanwhile, subcutaneous FcRn therapies from UCB ... to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines. Join the conversation, on Tuesday 28th January @ 10 am ET ...

It is administered through intramuscular and subcutaneous route. It has valency of 24, and it is a conjugate vaccine that contains a particular ratio of pneumococcal polysaccharides and pneumococcal ...

The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in ...

PCV21 is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter a Phase III clinical trial in infants and toddlers. Sanofi and SK Bioscience announced that they have ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

Rates of invasive pneumococcal disease are at their highest levels since 2004. While more effective vaccines have been approved for use in Australia, most at-risk people can't get them ...

The dangerous pneumococcal disease can be fatal to babies and children. Picture: CDC Pediatrician and infectious disease researcher Professor Peter Richmond said declining rates of vaccination ...